Xoma Corp. (XOMA) Forecasted to Post FY2016 Earnings of ($4.28) Per Share
Xoma Corp. (NASDAQ:XOMA) – Investment analysts at Jefferies Group upped their FY2016 EPS estimates for Xoma Corp. in a research report issued to clients and investors on Thursday. Jefferies Group analyst B. Amin now forecasts that the brokerage will earn ($4.28) per share for the year, up from their previous forecast of ($8.60). Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for Xoma Corp.’s Q4 2016 earnings at ($2.01) EPS, FY2017 earnings at ($4.11) EPS, FY2018 earnings at ($3.36) EPS, FY2019 earnings at ($2.86) EPS and FY2020 earnings at ($2.90) EPS.
Xoma Corp. (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($2.08) EPS for the quarter, beating the consensus estimate of ($2.40) by $0.32. The firm had revenue of $0.64 million for the quarter, compared to the consensus estimate of $1.29 million. The company’s revenue was down 69.1% on a year-over-year basis.
XOMA has been the topic of a number of other reports. Wedbush restated an “outperform” rating and issued a $3.00 price target (up from $1.42) on shares of Xoma Corp. in a research note on Friday, September 16th. Cowen and Company restated a “market perform” rating on shares of Xoma Corp. in a research note on Monday, September 19th. Finally, Zacks Investment Research upgraded Xoma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Wednesday, October 26th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.33.
Xoma Corp. (NASDAQ:XOMA) opened at 6.75 on Monday. Xoma Corp. has a 12 month low of $4.70 and a 12 month high of $32.40. The stock’s 50 day moving average price is $3.30 and its 200 day moving average price is $1.31. The company’s market capitalization is $40.70 million.
A number of institutional investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new position in Xoma Corp. during the second quarter valued at $185,000. Spark Investment Management LLC increased its position in shares of Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares during the last quarter. Wedbush Securities Inc. increased its position in shares of Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock valued at $223,000 after buying an additional 15,827 shares during the last quarter. Finally, Bellevue Group AG acquired a new position in shares of Xoma Corp. during the first quarter valued at approximately $174,000.
About Xoma Corp.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Stock Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related stocks with our FREE daily email newsletter.